Moreover, in a first line randomized phase III double-blind study (MONARCH 3) for ESR1+/HER2− advanced breast cancer, abemaciclib presented a better hematological tolerability compared to palpociclib and ribociclib, and achieved impressive results in terms of PFS and objective response rate (ORR) [71]. The gene discussed is ESR1; the disease is breast carcinoma.